+ Watch MDSO
on My Watchlist
As more healthcare providers are moving to the cloud, MDSO will definately benefit. People really underestimate the potential of the cloud.
Riding to cloud wave
Actually got in today at a lower price than is stated on my "entry price". Efficiency is one of the key components in the game for producing monumental ROI, if executed well. Few catalysts can rival the cost efficiencies of a well done SaaS model. MDSO has a laser focus and well articulated vision for being the best in class information supplier for Clinical Development Solutions within the life sciences vertical. This is an area rife with cost overruns and a penchant for in-efficiency. Time to market is a huge item that impacts profitability for all Biotech & Pharma companies. It stands to be even more critical in the Genomics category.MDSO has a customer retention rate and a demonstrated ability to capture new clients at an unprecedented rate. Matching this with a building SaaS business model and a growing silo of industry specific data and process models, I am glad to be joining them on this ride.It is still early and with a light enough float along with new capital coming on line, yes despite the dilution forthcoming, this for my money, is a buy and hold candidate. I do wish I would have found it earlier but I very content with starting my new position with them as of today.
They have succeeded in taking control of the clinical trials market, but this market is not subject to the stimulus the way the EHR market is.
SaaS cloud storage of medical records...genius
I think that Elan's Tysabri is becomming the best for all MS patients and only for this the stock can outperform the market. Elan also has several issues for the disease of Alsheimer and that can take the stock going like GILD did the past ten year.
The bottom for this company is thin . But the beauty inside is impressive . Robust revenue growth year by year . The cash flow is strong. Net income might be low but it is norm when your company is in growing mode. A lot of depreciation makes the bottom line look bad but CF is far more better. The revenue stream is recurring because it is in service business. 80% of customer retention . And the Biotech sector is blooming like Obama said and the aging economy . Everything looks great for this small company. So I would say "long term buy"
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions